Evidence map›Paper›PMID 40575429›Full record

ArticleWorld journal of cardiology2025

Long-term prognostic role of adiponectin in stable coronary artery disease: A meta-analysis of prospective studies.

Sahas Reddy Jitta, Priyanka Vatsavayi, Chenna Reddy Tera, Shobana Krishnamurthy, Saisree Reddy Adla Jala, Diksha Sanjana Pasnoor, Utheja Dasari, Aisha Farooq, Supriya Maramreddy, Kavya Jammula and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sahas Reddy JittaDepartment of Internal Medicine, Mercy Hospital, St Louis, MO 63141, United States.
Priyanka VatsavayiDepartment of Internal Medicine, East Tennessee State University, Johnson City, TN 37614, United States.
Chenna Reddy TeraDepartment of Internal Medicine, East Tennessee State University, Johnson City, TN 37614, United States.
Shobana KrishnamurthyDepartment of Internal Medicine, Tower Health, Reading, PA 19611, United States.
Saisree Reddy Adla JalaHospital Medicine, Mission Health, Asheville, NC 28801, United States.
Diksha Sanjana PasnoorDepartment of Medicine, Kamineni Acad of Medical Sciences and Research Center, Hyderabad 508254, India.
Utheja DasariDepartment of Internal Medicine, Trinity Health, Okland, MI 48341, United States.
Aisha FarooqDepartment of Medicine, Dr.Ruth K. M. Pfau, Civil Hospital, Karachi 74400, Sindh, Pakistan.
Supriya MaramreddyDepartment of Medicine, Kamineni Institute of Medical Sciences, Narketpally 508254, Telangāna, India.
Kavya JammulaDepartment of Medicine, Osmania General Hospital, Hyderabad 500012, Telangāna, India.
Medha Reddy KesaniDepartment of Medicine, Kamineni Institute of Medical Sciences, Narketpally 508254, Telangāna, India.
Sridevi TripuraneniDepartment of Internal Medicine, Kamineni Institute of Medical Sciences, Hyderabad 508254, Telangāna, India.
Nihar JenaDepartment of Interventional Cardiology, Marshall University, Huntington, WV 25701, United States.
Rupak DesaiDepartment of Outcomes Research, Independent Researcher, Atlanta, GA 30033, United States. drrupakdesai@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe persistent burden of cardiovascular (CV) disease in the United States requires innovative and cost-effective prognostic markers that can be relied upon.

aimTo provide insights into how adiponectin can predict all-cause mortality and major adverse CV events (MACE) in patients with coronary artery disease (CAD) and to determine the prognostic value of adiponectin in predicting all-cause mortality and MACE in patients with stable CAD.

methodsWe conducted a systematic search on PubMed, Scopus, and Google Scholar to find relevant studies published through June 2023 evaluating the long-term prognostic role of adiponectin in patients with stable CAD. Using a random effects model with 95%CI, we estimated the odds ratio (OR) while assessing heterogeneity through

resultsAfter screening, we included five prospective studies involving 3225 patients who were followed up for a median duration of 3.8 years. Within the study population, prevalent risk factors included hypertension, diabetes, hyperlipidemia, and smoking. The commonly prescribed medications were angiotensin-converting enzyme inhibitors, beta blockers, and statins. The combined adjusted OR for all-cause mortality was found to be 2.51 (95%CI: 1.36-4.62), showing heterogeneity (

conclusionHigher levels of adiponectin were found to be associated with an increased risk of long-term mortality and MACE in patients with CAD, which highlights its potential as a cost-effective marker for risk assessment and guiding treatment strategies. Further research on the role of adiponectin could greatly influence decision-making and resource allocation in CV care.

Indexed as

AdiponectinCoronary artery diseaseLong-termMajor adverse cardiac and cerebrovascular eventsMeta-analysisMortalityStable coronary artery diseaseSystematic review

Identifiers

PMID40575429
PMCPMC12186166

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.